Stock VRTX VERTEX PHARMACEUTICALS INCORPORATED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Vertex Pharmaceuticals Incorporated

Equities

VRTX

US92532F1003

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-10 pm EDT 		5-day change 1st Jan Change
422.8 USD +0.90% Intraday chart for Vertex Pharmaceuticals Incorporated +5.41% +3.91%
May. 10 Alpine Immune Sciences, Vertex Pharmaceuticals Deal Crosses Another Milestone MT
May. 07 FOMO is Back Our Logo

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 56,303 61,457 55,834 74,127 104,849 108,122 - -
Enterprise Value (EV) 1 52,495 54,798 48,309 63,349 93,630 94,148 89,109 84,069
P/E ratio 48.5 x 23 x 24.4 x 22.5 x 29.3 x 27.7 x 24.7 x 21.8 x
Yield - - - - - - - -
Capitalization / Revenue 13.5 x 9.9 x 7.37 x 8.3 x 10.6 x 10 x 9.23 x 8.44 x
EV / Revenue 12.6 x 8.83 x 6.38 x 7.09 x 9.49 x 8.75 x 7.61 x 6.57 x
EV / EBITDA 27.7 x 15.2 x 10.8 x 12.8 x 20.6 x 17.4 x 15.3 x 12.9 x
EV / FCF 35.1 x 18.3 x 20.1 x 16.1 x 28.1 x 22 x 18.8 x 15.3 x
FCF Yield 2.85% 5.46% 4.99% 6.2% 3.56% 4.54% 5.33% 6.52%
Price to Book 9.38 x 7.07 x 5.53 x 5.33 x 5.96 x 4.98 x 4.57 x 3.93 x
Nbr of stocks (in thousands) 257,150 260,038 254,252 256,691 257,683 258,053 - -
Reference price 2 219.0 236.3 219.6 288.8 406.9 419.0 419.0 419.0
Announcement Date 1/30/20 2/1/21 1/26/22 2/7/23 2/5/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 4,163 6,206 7,574 8,931 9,869 10,762 11,710 12,803
EBITDA 1 1,893 3,601 4,470 4,941 4,556 5,400 5,810 6,502
EBIT 1 1,786 3,491 4,344 4,793 4,375 5,035 5,434 6,169
Operating Margin 42.9% 56.25% 57.35% 53.67% 44.33% 46.78% 46.4% 48.19%
Earnings before Tax (EBT) 1 1,395 3,117 2,730 4,232 4,380 4,864 5,516 6,344
Net income 1 1,177 2,712 2,342 3,322 3,620 3,948 4,441 5,093
Net margin 28.27% 43.7% 30.92% 37.2% 36.68% 36.68% 37.92% 39.78%
EPS 2 4.510 10.29 9.010 12.82 13.89 15.13 16.99 19.18
Free Cash Flow 1 1,494 2,994 2,408 3,925 3,337 4,272 4,749 5,484
FCF margin 35.89% 48.24% 31.8% 43.95% 33.81% 39.69% 40.56% 42.83%
FCF Conversion (EBITDA) 78.92% 83.15% 53.89% 79.44% 73.24% 79.12% 81.75% 84.34%
FCF Conversion (Net income) 126.94% 110.4% 102.84% 118.16% 92.19% 108.2% 106.95% 107.68%
Dividend per Share 2 - - - - - - - -
Announcement Date 1/30/20 2/1/21 1/26/22 2/7/23 2/5/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 2,073 2,098 2,196 2,334 2,303 2,375 2,493 2,484 2,518 2,691 2,662 2,692 2,741 2,718 2,780
EBITDA 1 - - - - - - - 1,215 1,210 1,390 1,303 1,273 1,241 - -
EBIT 1 1,124 1,166 1,187 1,289 1,150 902.3 1,148 1,173 1,151 1,336 1,248 1,232 1,231 1,332 1,387
Operating Margin 54.23% 55.61% 54.05% 55.24% 49.95% 37.99% 46.04% 47.24% 45.73% 49.67% 46.87% 45.75% 44.89% 49% 49.9%
Earnings before Tax (EBT) 1 870.9 954.8 1,024 1,176 1,077 891.5 1,162 1,179 1,148 1,279 1,221 1,192 1,212 1,349 1,413
Net income 1 770.1 762.1 810.5 930.5 818.9 699.8 915.7 1,035 968.8 1,100 973.2 949.1 938.6 1,081 1,132
Net margin 37.16% 36.33% 36.9% 39.86% 35.56% 29.47% 36.73% 41.69% 38.48% 40.87% 36.55% 35.25% 34.24% 39.77% 40.74%
EPS 2 3.000 2.960 3.130 3.590 3.150 2.690 3.520 3.970 3.710 4.210 3.769 3.641 3.614 4.130 4.320
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 1/26/22 5/5/22 8/4/22 10/27/22 2/7/23 5/1/23 8/1/23 11/6/23 2/5/24 5/6/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 3,808 6,659 7,525 10,779 11,218 13,974 19,013 24,053
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 1,494 2,994 2,409 3,925 3,337 4,272 4,749 5,484
ROE (net income / shareholders' equity) 22.4% 36.7% 36% 32.1% 23% 22.3% 21.3% 21.6%
ROA (Net income/ Total Assets) 16.2% 27% 18.8% 21% 17.7% 15.3% 13.7% 13%
Assets 1 7,282 10,035 12,433 15,792 20,441 25,743 32,435 39,233
Book Value Per Share 2 23.30 33.40 39.70 54.10 68.20 84.10 91.70 107.0
Cash Flow per Share 2 6.020 12.40 10.20 15.90 13.60 18.80 19.10 20.30
Capex 1 75.5 260 235 205 200 216 217 221
Capex / Sales 1.81% 4.19% 3.1% 2.29% 2.03% 2% 1.85% 1.73%
Announcement Date 1/30/20 2/1/21 1/26/22 2/7/23 2/5/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Vertex Pharmaceuticals Incorporated

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
419 USD
Average target price
462.1 USD
Spread / Average Target
+10.29%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+3.91% 108B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+10.87% 104B
ARGENX SE Stock argenx SE
+1.28% 22.33B
BIONTECH SE Stock BioNTech SE
-13.14% 22.19B
GENMAB A/S Stock Genmab A/S
-7.05% 18.69B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-38.36% 17.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-10.66% 17.64B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.75% 14.05B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+36.70% 12.51B
VIKING THERAPEUTICS, INC. Stock Viking Therapeutics, Inc.
+295.70% 8.84B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. VRTX Stock
  4. Financials Vertex Pharmaceuticals Incorporated
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW